{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002295","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.025536+00:00","generated_at":"2026-06-07T02:07:41.913047+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS Life Sciences prices $9.0M public offering of 12M shares and warrants at $0.75/unit","bullets":["Gross proceeds of $9.0M from sale of 12M shares/common stock equivalents and 12M warrants at $0.75 per unit.","Warrants exercise price $0.75 per share, immediately exercisable, expire in five years.","A.G.P./Alliance Global Partners acting as sole placement agent; closing expected Jan 8, 2024.","Exercise price reduced to $0.75 on ~7.5M warrants from prior issuances; term extended to Jan 8, 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002295","json":"https://secwatch.observer/filing/0001104659-24-002295.json","markdown":"https://secwatch.observer/filing/0001104659-24-002295.md","text":"https://secwatch.observer/filing/0001104659-24-002295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/0001104659-24-002295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/tm242414d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:07:41.913047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b40a2224d33e40621ec461180c142f25e67b68be","claim":"SELLAS Life Sciences Group, Inc. entered into Securities Purchase Agreements with certain investors (the \"Purchasers\") valued at approximately $9.0 million (effective 2024-01-04).","evidence_excerpt":"On January 4, 2024, SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain investors (the “Purchasers).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/0001104659-24-002295-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors (the \"Purchasers\")"},{"label":"Value","value":"approximately $9.0 million"},{"label":"Effective","value":"2024-01-04"}],"fact_type":"material_agreement"},{"claim_id":"c8d6605130ff9b4e55f1540e1c7d32fad13c15c0","claim":"SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners (the \"Placement Agent\") (effective 2024-01-04).","evidence_excerpt":"On January 4, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company engaged the Placement Agent as the exclusive placement agent in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924002295/0001104659-24-002295-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners (the \"Placement Agent\")"},{"label":"Effective","value":"2024-01-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}